Pharma Reviews: Will Glenmark's attempts to unlock value of API, R&D units prove beneficial?

While Indian pharma companies increased their average R&D spend from 5.3 per cent in FY12 to 8.5 per cent in FY19, Glenmark's R&D expenditure ...
Read more: Will Glenmark's attempts to unlock value of API, R&D units prove beneficial?